: iStockAnalyst.com Symbols Feed

China Sky One Has Another 26 Products Awaiting Approval

Wed, 10 Sep 2008 17:49:00 GMT

China Sky One Medical, with its near-constant barrage of press releases, sometimes seems like an overactive child who always demands attention. On the other hand, the company’s insistent press release schedule is understandable because the company is grow[More...]

China Sky One’s Quarter 2 Beats Estimates

Wed, 13 Aug 2008 14:02:00 GMT

China Sky One Medical, Inc. released a very positive Q2 earnings report that also beat analysts’ expectations. Revenues increased 62% to $23.7 million, and net income tjumped 92% to $8.1 million or 50 cents per diluted share. Those results were higher than street estimates of $19.5 million and 37 cents per share. In addition to the numbers, China Sky One took pains to point to a number of company accomplishments during the quarter. More details... Stock Symbols: (AMEX: CSY)[More...]

China Sky One Reports 11 Drugs in Clinical Trials

Fri, 11 Jul 2008 18:33:00 GMT

China Sky One Medical reported that it has 11 new drugs in clinical trials, seven of them administered by injection. The clinical trials...[More...]

China Sky One to Launch Clot Buster Injection

Tue, 08 Jul 2008 18:31:00 GMT

China Sky One Medical, Inc. received production approval for three injected products, including a propyl gallate...[More...]

China Sky One Receives Four More Approvals

Thu, 19 Jun 2008 06:44:03 GMT

China Sky One Medical (AMEX: CSY) announced SFDA approval for another four new topically applied products: Tobramycin Eye Drops, Compound Zinc Sulfate Eye Drops, Ofloxacin Suppositories and Ofloxacin Gels.[More...]

ChinaBio: Week in Review: Deals and Drugs

Sun, 15 Jun 2008 19:42:00 GMT

Last week, the news item that could have the most profound effect on the China biomedical world, did not – paradoxically – involve a China biomedical company. The third largest pharmaceutical company in Japan, Daiichi Sankyo (TSE: 4568.JP), announced its[More...]

China Sky One Makes $7 Million Acquisition

Thu, 12 Jun 2008 18:14:37 GMT

[More...]

Some Potential Shorts & Advice

Wed, 11 Jun 2008 15:55:11 GMT

People ask me how many hours should they spend trading and researching each day and I think many are surprised with my answer: it depends on your personality, trading style and how much you wanna make. For some people it takes a few minutes, some take hou[More...]

China Sky One Ups Forecast; Hits New High

Tue, 10 Jun 2008 17:46:15 GMT

[More...]

China Sky One Granted Five Approvals

Tue, 03 Jun 2008 21:11:32 GMT

China Sky One Medical, Inc. reported it received SFDA approval for five new patch products,...[More...]

China Sky One Medical, Inc. Completes Acquisition of Peng Lai Jin Chuang Company

Thu, 11 Sep 2008 20:20:00 GMT

China Sky One Medical, Inc. , a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China , announced today that it completed the acquisition of Peng Lai Jin Chuang Company . The acquisition was announced on June 12, 2008 and closed on September 5, 2008.[More...]

China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials

Wed, 10 Sep 2008 11:57:00 GMT

China Sky One Medical, Inc. , a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China , announced today that it successfully developed 26 new drugs that are currently in clinical trials.[More...]

Analyst Reports for Taseko Mines Limited, Hanover Capital Mortgage Holdings Inc., Tanzanian Royalty Exploration Corporation and China Sky One Medical Inc.

Mon, 08 Sep 2008 17:02:00 GMT

MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world.
Investors seeking genuine analyst opinions on their investments for Taseko Mines Limited (AMEX: TGB), Hanover Capital Mortgage Holdings Inc. (AMEX: HCM), Tanzanian Royalty Exploration Corporation (AMEX: TRE) and China Sky One Medical Inc. (AMEX: CSY) should take this opportunity to get free in-depth research by signing up for a free membership at www.maybachfinancial.com.
Margin changes, specifically operating, gross, and then net -- Pace and quality of top line growth -- Ability to generate cash -- Pace and quality of the bottom line growth -- Market share gains -- Innovation/pipeline -- Corporate governance -- Management's ability to operate in unfavorable environments -- Ability of management to control acquisitive growth and achieve accretive results

[More...]

China Sky One Medical, Inc. to Present at SIG Beijing Management Summit

Mon, 08 Sep 2008 11:57:00 GMT

China Sky One Medical, Inc. , a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China , announced today that it will present at the upcoming second annual SIG Beijing Management Summit held September 10-12, 2008 at the Grand Hyatt Beijing Hotel in Beijing.[More...]

China Sky One Medical Announces Successful Marketing Campaign

Thu, 04 Sep 2008 11:58:00 GMT

China Sky One Medical, Inc. , a leading fully integrated pharmaceutical company producing external use, over-the-counter drugs in the People's Republic of China , today announced the results of its marketing campaign.[More...]

China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market

Tue, 02 Sep 2008 18:55:00 GMT

China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease

Thu, 14 Aug 2008 11:56:00 GMT

China Sky One Medical, Inc. Announces Record Second Quarter 2008 Results

Tue, 12 Aug 2008 11:59:00 GMT

China Sky One Medical, Inc. , a China based developer, manufacturer, marketer and international distributor of pharmaceutical, medicinal and diagnostic products, today announced record financial results for the second quarter ended June 30, 2008.[More...]

/C O R R E C T I O N -- China Sky One Medical, Inc./ - Jul 16 2008 10:06PM

Thu, 17 Jul 2008 01:18:00 GMT

In the news release, "China Sky One Medical, Inc. Signs Distribution Agreement with Harbin Baolong Pharmaceutical Company", issued by China Sky One Medical, Inc. over Xinhua PR Newswire on July 15, we are advised by the company that the third paragraph, first sentence, should read "The agreement, which initially runs over five years, has an estimated value of approximately RMB 61.5 million per year." rather than "The agreement, which initially runs over five years, has a total estimated value of approximately RMB 61.5 million " as originally issued inadvertently. Full, correct version follows:[More...]

China Sky One Medical, Inc. Signs Distribution Agreement with Harbin Baolong Pharmaceutical Company

Tue, 15 Jul 2008 07:24:00 GMT

China Sky One Medical, Inc. , a leading fully integrated pharmaceutical company producing external use, over- the-counter drugs in the People's Republic of China , announced today that it signed an agreement with Harbin Baolong Pharmaceutical Company on July 12 to distribute the Company's prescription drugs.[More...]